Scleroderma (Systemic Sclerosis): Early Signs, Organ Complications, and Management

What Is Scleroderma?

Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease characterized by fibrosis, vascular dysfunction, and autoimmunity. It exists on a spectrum from limited cutaneous (lcSSc) to diffuse cutaneous (dcSSc) forms.

Early Symptoms (Often Present for Years Before Diagnosis)

  • Raynaud's phenomenon: Triphasic color changes (white → blue → red) in fingers/toes triggered by cold/stress. Present in >95% of patients; often precedes other symptoms by years.
  • Puffy fingers / hand swelling: Non‑pitting edema, worse in morning.
  • Skin thickening: Starts distally (fingers, face), may spread proximally. Skin feels tight, shiny, hides wrinkles.
  • Gastrointestinal: Reflux (GERD), dysphagia, bloating, constipation/diarrhea (dysmotility).
  • Musculoskeletal: Arthralgias, myalgias, contractures (flexion).
  • Fatigue, weight loss, low‑grade fever.
  • Respiratory: Exertional dyspnea, dry cough (early ILD).
  • Digital ulcers/pitting scars: Ischemic fingertips.

Advanced / Late Complications (Organ‑Based)

Organ SystemComplications
LungsInterstitial lung disease (ILD) — fibrosis, honeycombing; Pulmonary arterial hypertension (PAH) — leading cause of death
HeartMyocardial fibrosis → diastolic dysfunction, heart failure, arrhythmias, pericarditis
KidneysScleroderma renal crisis (SRC): malignant hypertension, acute kidney injury, microangiopathic hemolysis (associated with anti‑RNA pol III, high‑dose steroids)
GISevere dysmotility: gastroparesis, pseudo‑obstruction, bacterial overgrowth, malabsorption, fecal incontinence
VascularSevere digital ischemia → gangrene, amputation; telangiectasias
OtherCalcinosis cutis, sicca syndrome (overlap Sjögren's), increased malignancy risk (lung, liver)

Key Autoantibodies (Prognostic)

  • Anti‑centromere: Limited cutaneous; lower ILD risk, higher PAH risk.
  • Anti‑Scl‑70 (topoisomerase I): Diffuse cutaneous; high ILD risk.
  • Anti‑RNA polymerase III: Diffuse; high SRC risk, rapid skin progression.
  • Anti‑U3 RNP (fibrillarin): Diffuse; PAH, cardiac, GI involvement.

Management Principles

  • Multidisciplinary care (rheumatology, pulmonology, cardiology, nephrology, GI, dermatology).
  • Raynaud's: CCBs (nifedipine), PDE‑5 inhibitors, prostanoids (IV iloprost).
  • ILD: Mycophenolate, cyclophosphamide, nintedanib, tocilizumab.
  • PAH: ERA, PDE‑5i, prostacyclin pathway agents.
  • SRC: ACE inhibitors (captopril) — lifesaving if started early.
  • Skin: Immunosuppressants (MMF, methotrexate) for early dcSSc.

Multiple Sclerosis - Related Articles